Pfizer’s Litfulo is already approved in alopecia areata; however, the success of the TRANQUILLO programme sets it up for potential approval in NSV.

The post Pfizer seeks label expansion for Litfulo after double Phase III NSV win appeared first on Clinical Trials Arena.